Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aurora Cannabis Inc. ACB NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
60/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.92
+67.7%

Aurora Cannabis Inc. (ACB) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.53. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ACB = $6 (+67.7% upside).

Valuation: ACB trades at a trailing Price-to-Earnings (P/E) of -6.3 (S&P 500 average ~25).

Financials: revenue is $343M, +16.1%/yr average growth. Net income is $2M, growing at +86.9%/yr. Net profit margin is 0.5% (thin). Gross margin is 54.6% (+45 pp trend).

Balance sheet: total debt is $105M against $567M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 4.31 (strong liquidity). Debt-to-assets is 12.3%. Total assets: $853M.

Analyst outlook: 3 / 14 analysts rate ACB as buy (21%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 52/100 (Partial), Income 30/100 (Fail).

$5.92
▲ 67.71% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Aurora Cannabis Inc., the average price target is $5.92, with a high forecast of $8.75, and a low forecast of $1.00.
Highest Price Target
$8.75
Average Price Target
$5.92
Lowest Price Target
$1.00

ACB SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACB

✓
VALUE Pass
100/100
ACB trades at a trailing Price-to-Earnings (P/E) of -6.3 (S&P 500 average ~25). Forward PEG -0.05 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.13. Analyst consensus target is $6, implying +70% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
ACB: +16.1%/yr revenue is, +86.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ACB: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet ACB: Debt-to-Equity (D/E) ratio 0.18 (conservative), Current ratio is 4.31 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
ACB: Gross margin is 54.6% (+45 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 3 / 14 analysts rate ACB as buy (21%). Analyst consensus target is $6 (+70% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
30/100
ACB: Net profit margin is 0.5%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.07-6.665
Volume436.24K
Avg Volume (30D)837.77K
Market Cap$200.18M
Beta (1Y)1.32
Share Statistics
IPO Date2014-07-15
Employees1,073
CEOMiguel Martin
Financial Highlights & Ratios
Revenue (TTM)$343.29M
Gross Profit$187.61M
EBITDA$51.35M
Net Income$1.59M
Operating Income$4.95M
Total Cash$138.48M
Total Debt$104.58M
Net Debt$-33.34M
Total Assets$852.67M
Price / Sales (P/S)0.58
Analyst Forecast
1Y Price Target$8.00
Target High$8.75
Target Low$1.00
Upside+126.6%
Rating ConsensusHold
Analysts Covering14
Buy 21% Hold 57% Sell 21%
Price Target Summary
Company Info
CountryCA
ExchangeNASDAQ Global Select
CurrencyUSD
ISINCA05156X8504

Price Chart

Track all markets on TradingView
ACB
Aurora Cannabis Inc. ↗  ·  NASDAQ Global Select
Healthcare • Drug Manufacturers - Specialty & Generic
3.07 52WK RANGE 6.67

People Also View

CURLF
CURLF
Curaleaf Holdings, Inc.
$2.40
+0.04%
 CRON
CRON
Cronos Group Inc.
$2.57
+0.78%
 TLRY
TLRY
Tilray Brands, Inc.
$6.91
+2.83%
 CGC
CGC
Canopy Growth Corporation
$1.09
+0.93%
 SNDL
SNDL
SNDL Inc.
$1.44
+5.11%
 OGI
OGI
Organigram Global Inc.
$1.43
+0.70%
 HEXO
HEXO
HEXO Corp.
$0.71
+2.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message